

Appendix –Supplementary Materials

Table 4: ALGORITHM FOR DETERMINING DIALYSIS TREATMENT FREQUENCY PRIORITY

PRIORITY A	<ul style="list-style-type: none"> • Average interdialytic weight gain \geq <u>2 kg</u> during the <u>last month</u> <p>OR</p> <ul style="list-style-type: none"> • Cannot miss based on opinion of treating physician e.g. inability to tolerate small weight gains due to tenuous cardiac status, non-adherent with Kayexalate, etc. 	Cannot miss any treatments safely
PRIORITY B	<ul style="list-style-type: none"> • <u>2 or more</u> K values >5.5 mEq/L during the <u>last 3 months</u> 	<p>Ideally should not miss any treatments</p> <p>If must miss one treatment, use sodium polystyrene sulfonate (Kayexalate) 30 g daily until next treatment, or another approved potassium-binder.</p>
PRIORITY C	<ul style="list-style-type: none"> • one K value >5.5 mEq/L in the <u>last 3 months</u> 	<p>*Can temporarily miss one treatment in a week if absolutely necessary.</p> <p>Prescribe sodium polystyrene sulfonate (Kayexalate) 15 g daily until next treatment or another approved potassium-binder.</p>
PRIORITY D	<ul style="list-style-type: none"> • All others 	<p>*Can temporarily miss one treatment in a week if absolutely necessary</p> <p>The need for Kayexalate should be determined by the treating physician based on knowledge of the patient’s average K, adherence, and residual kidney function</p>

This algorithm was developed for use with Nephrocare electronic medical record (EMR), but could also be applied with other EMRs.

*Patient should not miss two consecutive treatments, *and if possible, no more than two treatments in 6 weeks.*

*Patients with serious dialysis access related issues with decreased blood flows and potential pre-existing underdialysis should NOT miss any treatments.

*Treating physician has the discretion to override this algorithm for individual patients.

Table 5: CRITERIA for initiating and maintaining TWICE WEEKLY HEMODIALYSIS treatment ^{1,2,3}

<ul style="list-style-type: none"> ▪ Adequate KRU of >3 ml/min/1.73m² (requires prior 24-hour urine collection available). KRU = residual urea clearance¹ ▪ Adequate residual urine output >600 ml/day ▪ Fluid gain <2.5kg between two consecutive HD treatments, or $<5\%$ of the ideal dry weight ▪ No clinically significant fluid overload ▪ Suitable body size relative to residual kidney function and not in hypercatabolic state ▪ $K <5.5$ mEq/L ▪ Good nutritional status ▪ Infrequent hospitalization and easily manageable comorbid conditions including cardiovascular or pulmonary symptoms
